


LEARN THE DIFFERENCE BETWEEN VISION CORRECTION PROCEDURES

AND ASK YOUR EYE CARE PROFESSIONAL FOR MORE DETAILS.



^{*}Visian ICL offers correction for hyperopia. Peripheral irodotomy is needed prior to treatment.

Important Safety Information for EVO/EVO+ ICL

Implantation of the EVO/EVO+ ICL is a surgical procedure, and as such, carries potentially serious risks. The EVO/EVO+ ICL is designed for the correction/reduction of up to -20.0 diopters (D) of nearsightedness with up to 6.0 D of astigmatism for patients who are 21 to 60 years of age. Before considering EVO/EVO+ ICL surgery you should have a complete eye examination and talk with your eye care professional about the procedure, especially the potential benefits, risks, and complications. You should discuss the time needed for healing after surgery. For additional information with potential benefits, risks and complications please visit DiscoverICL.com.

For Professional Use Only IN-EVO ICL-25-0101

^{**} There is limited flexibility if future procedures involve the cornea.

^{1.} Albo C, et al. A Comprehensive Retrospective Analysis of EVO/EVO+ Implantable Collamer Lens: Evaluating Refractive Outcomes in the Largest Single Center Study of ICL Patients in the United States. Clin Ophthalmol. 2024 Jan 9;18:69-78.

^{2.} Ganesh S, Brar S, Pawar A. Matched population comparison of visual outcomes and patient satisfaction between 3 modalities for the correction of low to moderate myopic astigmatism. Clin Ophthalmol. 2017;11:1253-1263.

^{3.} Zhang H, Deng Y, Ma K, Yin H, Tang J. Analysis on the changes of objective indicators of dry eye after implantable collamer lens (ICL) implantation surgery. Graefes Arch Clin Exp Ophthalmol. 2024 Jul;262(7):2321-2328.

^{4.} Shoja MR, Besharati MR. Dry eye after LASIK for myopia: Incidence and risk factors. Eur J Ophthalmol. 2007;17(1):1-6.

^{5.} Lee JB, Ryu CH, Kim JH, et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. J Cataract Refract Surg. 2000;26(9):1326-1331.

^{6.} Martínez-Plaza E, López-Miguel A, López-De La Rosa A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life, Am J Ophthalmol. 2021;226: 117–125.

^{7.} Packer M. Evaluation of the EVO/EVO+ Sphere and Toric Visian ICL: Six month results from the United States Food and Drug Administration Clinical Trial. Clin Ophthalmol. 2022;16:1541-53.